RSS Feed Print
Why Eli Lilly's Alzheimer's Imaging Test Is No Breakthrough
Myriam
Posted: Tuesday, April 10, 2012 2:44 PM
Joined: 12/6/2011
Posts: 3326


From Alzheimer's Daily News:


(Source: Forbes) - Take the way shares of Eli Lilly are reacting to the news that the Food and Drug Administration approved the company's imaging agent for understanding and diagnosing Alzheimer's disease. Lilly shares have fallen 1.3% along with the broader market. Not exactly what you'd expect if the drug, Amyvid (florbetapir) is going to be widely used to diagnose one of the most dreaded diseases in the world, as you might expect after reading this Wall Street Journal article.


The problem, straight from the drug's label: "A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder."

 

The idea behind the drug is wonderful, and really could change the way Alzheimer's is diagnosed and treated over the long-term. It's an imaging agent that allows radiologists to see signs of the diseases on a Positron Emission Tomography (PET) scan, potentially allowing for earlier diagnosis. Right now, the test will be used mainly to rule out Alzheimer's - patients who have no brain plaque don't have Alzheimer's. A positive result actually doesn't mean the patient has Alzheimer's.

 

Go to full story: http://www.forbes.com